This is the first large multicenter clinical series of the Bryan Cervical Disc Prosthesis, a motion-preserving cervical arthroplasty. It asks whether replacing a degenerated cervical disc with a functional prosthesis after discectomy can relieve neurological symptoms while maintaining motion. The rationale is to avoid the adjacent-level stress attributed to fusion.
The central decision this paper informs: when treating single-level cervical radiculopathy or myelopathy, should you fuse or preserve motion?
The theoretical case for arthroplasty is that fusion increases stress and motion at adjacent levels, accelerating their degeneration at roughly 3% per year. This paper shows arthroplasty is feasible and safe short-term, with neurological outcomes driven mainly by the adequacy of decompression rather than the device itself.
Read the evidence critically. Success was defined generously (fair outcomes counted), effect size was not measured, and comparisons were made against historical fusion cohorts rather than a randomized control arm.
The adjacent-segment protection that justifies arthroplasty was not demonstrated here and remains debated. This is a proof-of-concept first report, not proof that arthroplasty prevents adjacent-level disease.
This is the first large multicenter clinical series of the Bryan Cervical Disc Prosthesis, a motion-preserving cervical arthroplasty. It asks whether replacing a degenerated cervical disc with a functional prosthesis after discectomy can relieve neurological symptoms while maintaining motion. The rationale is to avoid the adjacent-level stress attributed to fusion.
The central decision this paper informs: when treating single-level cervical radiculopathy or myelopathy, should you fuse or preserve motion?
The theoretical case for arthroplasty is that fusion increases stress and motion at adjacent levels, accelerating their degeneration at roughly 3% per year. This paper shows arthroplasty is feasible and safe short-term, with neurological outcomes driven mainly by the adequacy of decompression rather than the device itself.
Read the evidence critically. Success was defined generously (fair outcomes counted), effect size was not measured, and comparisons were made against historical fusion cohorts rather than a randomized control arm.
The adjacent-segment protection that justifies arthroplasty was not demonstrated here and remains debated. This is a proof-of-concept first report, not proof that arthroplasty prevents adjacent-level disease.